Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sugammadex - Merck & Co.

Drug Profile

Sugammadex - Merck & Co.

Alternative Names: Bridion; MK-8616; ORG-25969; SCH-900616; Sugammadex; Sugammadex sodium injection

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Organon
  • Developer Merck & Co
  • Class Gamma-Cyclodextrins; Muscle relaxants
  • Mechanism of Action Binding agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuromuscular blockade

Most Recent Events

  • 27 Oct 2017 Launched for Neuromuscular blockade in USA (IV)
  • 15 Dec 2015 Registered for Neuromuscular blockade in USA (IV)
  • 06 Nov 2015 The Anaesthetic and Analgesic Drug Products Advisory Committee of the US FDA recommends approval of sugammadex for Neuromuscular blockade in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top